1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Patient demographics, TNM stages, and therapy^{^a}
Demographics and Staging 
Age (yr) 
    Median 61
    Range 21–89
Sex 
    Male 388 (76%)
    Female 124 (24%)
Site of origin (n = 419) 
    Oropharynx 130 (31%)
    Oral cavity 130 (31%)
    Larynx 63 (15%)
    Maxillofacial/sinus 37 (9%)
    Hypopharynx 26 (6%)
    Nasopharynx 12 (3%)
    Trans-spatial 10 (2%)
    Unknown primary 8 (2%)
T stage (n = 428) 
    T0 9 (2%)
    T1 109 (25%)
    T2 124 (29%)
    T3 85 (20%)
    T4 101 (24%)
N stage (n = 440) 
    N0 192 (44%)
    N1 69 (16%)
    N2 162 (37%)
    N3 17 (4%)
M stage (n = 369) 
    M0 365 (99%)
    M1 4 (1%)
Therapy (n = 512) 
    CRT alone 67 (13%)
    Surgery plus CRT 445 (87%)
Note:—CRT indicates chemoradiation therapy; N, node; M, metastasis.
↵a A total of 512 patients were included in this study, but not all patients had initial staging data available, so fewer patients are included. The number of patients with available data is listed in the header for each section.